Pfizer pays $49.8mm for remainder of partner Icagen
In its second recent acquisition to build up pain management capabilities, Pfizer Inc. is buying public ion channel modulation firm Icagen Inc. The Big Pharma will pay $6 per share (a 9% discount) for the 89% of Icagen’s shares (approximately 8.3mm) that it didn’t already own, amounting to a total of $49.8mm. Pfizer indicated a possible takeover in late June, after the company filed a Schedule 13D with the SEC. At that time, the parties entered into preliminary discussions.
Drug Discovery Tools
- Drug Discovery Tools
- Includes Contract
- Partial Acquisition
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.